Precigen, Inc. (NASDAQ:PGEN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Precigen, Inc. (NASDAQ:PGEN) have earned an average rating of “Moderate Buy” from the five research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $14.50.

A number of research firms have commented on PGEN. Citizens Jmp raised their price target on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. Zacks Research raised Precigen from a “hold” rating to a “strong-buy” rating in a report on Wednesday, August 5th. HC Wainwright increased their price objective on shares of Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Citigroup reissued an “outperform” rating on shares of Precigen in a report on Thursday, May 14th. Finally, Wall Street Zen upgraded shares of Precigen from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 8th.

Precigen Price Performance

NASDAQ PGEN opened at $6.95 on Friday. The company has a current ratio of 4.58, a quick ratio of 3.89 and a debt-to-equity ratio of 2.15. Precigen has a 12 month low of $2.99 and a 12 month high of $7.72. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of -6.68 and a beta of 1.02. The company’s 50 day moving average is $6.05 and its two-hundred day moving average is $4.75.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. The firm had revenue of $54.98 million during the quarter, compared to analysts’ expectations of $27.98 million. Precigen’s revenue for the quarter was up 6322.7% on a year-over-year basis. As a group, research analysts anticipate that Precigen will post 0.25 earnings per share for the current year.

Insider Transactions at Precigen

In other Precigen news, COO Rutul R. Shah sold 42,924 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $5.85, for a total transaction of $251,105.40. Following the completion of the transaction, the chief operating officer owned 497,751 shares in the company, valued at $2,911,843.35. This trade represents a 7.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Harry Jr. Thomasian sold 171,429 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $5.53, for a total value of $948,002.37. Following the sale, the chief financial officer directly owned 354,535 shares in the company, valued at $1,960,578.55. This trade represents a 32.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 991,271 shares of company stock worth $6,208,620. 41.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Precigen

Several institutional investors have recently bought and sold shares of the business. Xponance LLC increased its holdings in shares of Precigen by 21.3% in the 4th quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,496 shares during the last quarter. BNP Paribas Financial Markets grew its position in Precigen by 6.1% in the third quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock worth $170,000 after acquiring an additional 2,993 shares in the last quarter. Composition Wealth LLC increased its stake in Precigen by 16.5% during the fourth quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 3,000 shares during the last quarter. Intech Investment Management LLC raised its position in Precigen by 5.2% during the fourth quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock valued at $263,000 after purchasing an additional 3,137 shares during the period. Finally, Cetera Investment Advisers lifted its stake in shares of Precigen by 0.9% in the 1st quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company’s stock valued at $1,449,000 after purchasing an additional 3,250 shares during the last quarter. Institutional investors own 33.51% of the company’s stock.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.